Genome editing company Precision proposes $100M IPO

With plans to bring an allogeneic CAR T immunotherapy into the clinic, Precision BioSciences Inc. (Durham, N.C.) proposed March 1 to raise up to $100 million in an IPO on NASDAQ.

Precision plans to start this half a Phase I/IIa trial of lead program, PBCAR0191, in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). The allogeneic CAR T cell therapy targeting CD19 has Orphan Drug designation in the U.S. to treat ALL...